Pharma Asia. News, analysis and practical guides on Pakistan’s pharmaceutical industry, from the team behind Pharma Asia, Pakistan’s biggest pharma sector exhibition.
Pakistan’s first vaccine policy starts with fill-and-finish and aims for full production. With Gavi support ending in 2031, the clock is running.
Eli Lilly credits AI with producing more medicine than it otherwise could; agentic AI is halving deviation investigations. What is real, and what it…
Cost, scale and concentration make China central to generic APIs. Tariffs, rebates and quality enforcement are changing the picture.
Everything a trade visitor needs for the three days: the E-Pass, opening hours, the seven halls and the convention.
With crossings to Pakistan’s largest medicine market shut since October 2025, exports fell 27.67% in July–February FY26. What exporters are facing.
PPMA chairmen, a DRAP director and company heads on why the exhibition and convention matter for Pakistan’s pharmaceutical sector.
The Finance Minister announced the full removal of customs duty on raw materials for locally made medicines, including cancer treatments.
DRAP’s SRO 963(I)/2026 requires Data Matrix codes and serial numbers on medicines made or imported from 9 October 2026.
Zavod Medsintez and Genetics Pharmaceuticals plan an aseptic filling plant by 2028 and insulin API production by 2031.
Europe’s revised sterile-manufacturing rules require a contamination control strategy and favour barrier technology. Why it matters beyond Europe.
Biocatalysis and greener solvents cut steps and waste. The world’s leading drug makers are investing — and the tools are openly shared.
A quick guide to the 2026 exhibitor list: how many companies are in each hall, where the Chinese exhibitors are, and some of the names to look for.
